Company intelligence / Profile preview

Vivostat

Ownership: Private
Employees: ~16
Development stage: Commercial

Overview

Vivostat’s system has been used in over 200,000 surgical procedures with peer-reviewed evidence showing zero rejection or infection rates. The company’s products are CE-marked and widely used across Europe for surgical hemostasis, tissue sealing, and regenerative medicine. The company has been profitable for the last three years

Therapeutic areas: OtherHematology
Modalities: DeviceBiologic (Autologous fibrin sealant)Platelet-rich fibrin matrix (PRF)
Industry: Biotech

Drug pipeline

1 asset

Vivostat

Unknown

Partnerships

TRB Chemedica UK – exclusive sales & marketing agreement for ArthroZheal® in the UK/Ireland

Beyond the preview

Go deeper on Vivostat.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vivostat.

Explore the full profile